Rhts-034 |link| Today

Hypertension remains a leading cause of cardiovascular morbidity and mortality worldwide. Despite the availability of multiple antihypertensive classes, a significant subset of patients fail to achieve target blood pressure goals, a condition known as resistant hypertension (RHTN). RHTS-034 is a novel, small-molecule, dual-acting vasodilator currently under investigation for the management of RHTN. This white paper reviews the pharmacological profile, proposed mechanism of action, preclinical efficacy, and potential clinical utility of RHTS-034.

: Such as the Queensland Health Guideline on Neonatal Jaundice or specific radiotherapy protocols like RTOG 0534 . rhts-034

Resistant hypertension is defined as blood pressure that remains above goal despite the concurrent use of three antihypertensive agents of different classes, including a diuretic, at optimal doses. The pathophysiology of RHTN often involves volume overload, excessive vasoconstriction, and neurohormonal activation. Current therapeutic options are limited, creating a critical need for novel agents. RHTS-034 has been engineered to address the multifactorial nature of this condition through a unique dual mechanism. The pathophysiology of RHTN often involves volume overload,